| abstract |
The present invention relates to combinations of lasmiditan and a calcitonin gene-related peptide (CGRP) antagonist, for example the combination of lasmiditan and galcanezumab, and to methods of using the combinations for treatment of migraine, particularly migraine inadequately controlled by lasmiditan or a CGRP antagonist therapy alone, and more particularly, to treat therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment regimens. |